Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HZ-H08905 in relapsed or refractory non-Hodgkin lymphoma
ChiCTR2600132942Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of HZ-H08905 in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), peripheral T-cell lymphoma (PTCL) and 4 more (3 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Objective response rate. Started Nov 2025; status: recruiting.
02
Drugs
HZ-H08905
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)peripheral T-cell lymphoma (PTCL)anaplastic large cell lymphoma (ALCL)extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on ChiCTR2600132942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132942.